Dean J. Kereiakes, MD, FACC, MSCAI

President, The Christ Hospital Heart and Vascular Institute; Medical Director, The Christ Hospital Research Institute; Professor of Clinical Medicine, The Ohio State University
The Christ Hospital Health Network
Cincinnati, Ohio, United States

Dean J. Kereiakes, M.D., FACC, MSCAI is President and Medical Director of The Christ Hospital Heart and Vascular Institute and Professor of Clinical Medicine at Ohio State University. He was valedictorian of his graduating class at the University of Cincinnati College of Medicine. His postgraduate training was at the University of California, San Francisco and the Massachusetts General Hospital. Dr. Kereiakes has been national/international Principal Investigator for more than 20 novel technologies and has been involved in more than a dozen first human use therapies. He has published over 1,100 journal articles, abstracts and book chapters, has served as section Editor for Circulation and is currently Deputy Editor for the journal of the Society for Cardiovascular Angiography and Interventions.

Presentation(s):

• BRS, DES and DCB Technologies (Non-CME)

  Sunday, February 26, 2023
  2:00 PM – 5:55 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• DCB FOR CORONARY AND PERIPHERAL APPLICATIONS

  Sunday, February 26, 2023
  2:00 PM – 2:32 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Virtue Sirolimus-Angio-Infusion Balloon

  Sunday, February 26, 2023
  2:56 PM – 3:02 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Panel Discussion: Will DCB Play a Role for Coronary Application in the US?

  Sunday, February 26, 2023
  3:34 PM – 3:50 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• New DES on the Horizon (Svelte/OPTIMIZE | BuMA Supreme/PIONEER III)

  Sunday, February 26, 2023
  4:38 PM – 4:46 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Discussion: Is there a Role/Need for Bioresorbable and/or Bioadaptor Platforms?

  Sunday, February 26, 2023
  4:54 PM – 5:18 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• NEW ANTICOAGULATION AND DAPT UPDATE

  Sunday, February 26, 2023
  5:18 PM – 5:55 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Panel Discussion: Optimal Duration of DAPT - How to Optimize Future Study Designs

  Sunday, February 26, 2023
  5:42 PM – 5:55 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Multi-center Compassionate Use Early Feasibility Evaluation Of J-valve Transcatheter Treatment For Severe Aortic Valve Regurgitation: Preliminary Results

  Monday, February 27, 2023
  2:24 PM – 2:32 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• J Valve for Aortic Regurgitation

  Tuesday, February 28, 2023
  9:38 AM – 9:46 AM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Panel Discussion | Second- and Third-Generation Aortic Valve Systems not Approved in the US Yet

  Tuesday, February 28, 2023
  10:18 AM – 10:30 AM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)

• Should Short DAPT and DAPT De-Escalation be Class 1 Recommendations

  Tuesday, February 28, 2023
  12:34 PM – 12:42 PM ET

  Disclosure(s): Elixir Medical: Consultant (Ongoing); JC Medical: Consultant (Ongoing); Orchestra Biomed: Consultant (Ongoing); Shockwave Medical Inc: Consultant (Ongoing); Svelte Medical: Consultant (Ongoing)